Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
point decrease » point increase (Expand Search)
decrease risk » increased risk (Expand Search), increases risk (Expand Search), disease risk (Expand Search)
part decrease » bfrt decreased (Expand Search), a decrease (Expand Search), pa decreased (Expand Search)
Showing 41 - 60 results of 19,764 for search '(( significant decrease risk ) OR ( significant ((part decrease) OR (point decrease)) ))', query time: 0.63s Refine Results
  1. 41
    Switching patterns of ICS/LABA.

    Switching patterns of ICS/LABA. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  2. 42
    Factors associated with exacerbations.

    Factors associated with exacerbations. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  3. 43
    Definition of each exacerbation.

    Definition of each exacerbation. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  4. 44
    Definitions of treatment step classification.

    Definitions of treatment step classification. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  5. 45
    Sensitivity analyses of breakthrough exacerbations.

    Sensitivity analyses of breakthrough exacerbations. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  6. 46
    Baseline characteristics of patients.

    Baseline characteristics of patients. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  7. 47
    Data for primary and sensitivity analysis.

    Data for primary and sensitivity analysis. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  8. 48
    Study design.

    Study design. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  9. 49
    Odds ratios for each case period compared with the control period.

    Odds ratios for each case period compared with the control period. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  10. 50
    Sensitivity analysis of the group who had an exacerbation before the index date.

    Sensitivity analysis of the group who had an exacerbation before the index date. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  11. 51
    Initial post-switch visits and SABA prescriptions in each period.

    Initial post-switch visits and SABA prescriptions in each period. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  12. 52
    Flow of eligible patients.

    Flow of eligible patients. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  13. 53
    ICS/LABA before and after switch.

    ICS/LABA before and after switch. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  14. 54
    Diseases excluded from the analysis.

    Diseases excluded from the analysis. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  15. 55
    Photo of the fruiting bodies of the oyster mushroom cultivated in the test conditions by anatomical part.

    Photo of the fruiting bodies of the oyster mushroom cultivated in the test conditions by anatomical part. by Agnieszka Zawadzka (11902224)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  16. 56
    Points of convergence / divergence between qualitative and quantitative findings.

    Points of convergence / divergence between qualitative and quantitative findings. by Emma Murphy (2270992)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  17. 57
    6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations

    6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 58
    6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations

    6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 59
    6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations

    6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 60
    6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations

    6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: